Data Insights

Abemaciclib by Eli Lilly and Co for Neuroblastoma: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Neuroblastoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Neuroblastoma

Data Insights

Abemaciclib by Eli Lilly and Co for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Renal Cell Carcinoma....

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Metastatic Renal Cell Carcinoma

Data Insights

Abemaciclib by Eli Lilly and Co for Dedifferentiated Liposarcoma: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Dedifferentiated Liposarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Dedifferentiated Liposarcoma

Data Insights

Abemaciclib by Eli Lilly and Co for Breast Cancer: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Breast Cancer

Data Insights

Abemaciclib by Eli Lilly and Co for Metastatic Breast Cancer: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Metastatic Breast Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Metastatic Breast Cancer

Data Insights

Abemaciclib by Eli Lilly and Co for Ewing Sarcoma: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Ewing Sarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Ewing Sarcoma

Data Insights

Abemaciclib by Eli Lilly and Co for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Transitional Cell Cancer (Urothelial...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

Abemaciclib by Eli Lilly and Co for Central Nervous System (CNS) Tumor: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Central Nervous System (CNS)...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Central Nervous System (CNS) Tumor

Data Insights

Abemaciclib by Eli Lilly and Co for Endometrial Cancer: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Endometrial Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Endometrial Cancer

Data Insights

Abemaciclib by Eli Lilly and Co for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Abemaciclib by Eli Lilly and Co for Malignant Mesothelioma: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Malignant Mesothelioma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Malignant Mesothelioma

Data Insights

Abemaciclib by Eli Lilly and Co for Fallopian Tube Cancer: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Fallopian Tube Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Fallopian Tube Cancer

Data Insights

Abemaciclib by Eli Lilly and Co for Peritoneal Cancer: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Peritoneal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Peritoneal Cancer

Data Insights

Abemaciclib by Eli Lilly and Co for Epithelial Ovarian Cancer: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Epithelial Ovarian Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Epithelial Ovarian Cancer

Data Insights

Abemaciclib by Eli Lilly and Co for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Pediatric Diffuse Intrinsic Pontine...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Pediatric Diffuse Intrinsic Pontine Glioma

Data Insights

Abemaciclib by Eli Lilly and Co for Kaposi Sarcoma: Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Kaposi Sarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Kaposi Sarcoma

Data Insights

Abemaciclib by Eli Lilly and Co for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Triple-Negative Breast Cancer (TNBC)....

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Triple-Negative Breast Cancer (TNBC)

Data Insights

Abemaciclib by Eli Lilly and Co for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Bile Duct Cancer (Cholangiocarcinoma)